Company news
Avalyn Pharma Inc. (NASDAQ:AVLN) news
Avalyn Pharma Inc. news releases on 6ix. Latest, Sep 16, 2026: Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
Press releases & updates
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
September 16, 2026
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
September 8, 2026
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
August 24, 2026
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
June 17, 2026
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
June 2, 2026
Avalyn to Participate in the Jefferies Global Healthcare Conference
May 27, 2026
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
May 21, 2026
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
May 5, 2026
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 30, 2026
Avalyn Announces Pricing of Upsized Initial Public Offering
April 28, 2026
Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury
April 27, 2026
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
April 6, 2026